A Liberian man being treated for Ebola in a Dallas hospital is still in critical condition, but is now receiving an experimental treatment.
Thomas Eric Duncan has been in isolation at Texas Health Presbyterian Hospital since Sept. 28, after he came down with symptoms of Ebola days after arriving in Texas from Liberia.
Health officials are still monitoring 50 people thought to have possibly come into contact with Duncan. His girlfriend, her son and two other men living at an apartment where Duncan had stayed have been moved to a private residence while the apartment is cleaned. None of them have developed symptoms of Ebola.
Officials over the weekend downgraded Duncan from serious to critical condition, and officials reported Sunday he was on a respirator and fighting for his life.
Chimerix confirmed in a statement that the drug “has been provided for potential use in patients with Ebola.” Doctors treating patients had requested the drug, the company said, and the request was granted by the Food and Drug Administration through the Emergency Investigational New Drug Application process.
The FDA does not comment on specific drug applications.
The company is testing the drug's efficacy against Ebola in animal subjects.